ECMO is used for patients with life-threatening heart or lung disease or damage. It provides short-term support of the cardiac or pulmonary system when conventional management fails.
A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a real world study sponsored by AstraZeneca.